Model‐Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development

Systematic implementation of model‐based drug development (MBDD) to drug discovery and development has the potential to significantly increase the rate of medical breakthroughs and make available new and better treatments to patients. An analysis of the strengths, weaknesses, opportunities, and threats (ie, SWOT) was conducted through focus group discussions that included 24 members representing 8 pharmaceutical companies to systematically assess the challenges to implementing MBDD into the drug development decision‐making process. The application of the SWOT analysis to the successful implementation of MBDD yielded 19 strengths, 27 weaknesses, 34 opportunities, and 22 threats, which support the following conclusions. The shift from empirical drug development to MBDD requires a question‐based mentality; early, proactive planning; dynamic access to multisource data; quantitative knowledge integration; multidisciplinary collaboration; effective communication and leadership skills; and innovative, impactful application of pharmacometrics focused on enhancing quantitative decision making. The ultimate goal of MBDD is to streamline discovery and development of innovative medicines to benefit patients.

[1]  I. Kola,et al.  The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.

[2]  Rajesh Krishna,et al.  Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  Innovation OR Stagnation.  Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[4]  Heinz Weihrich,et al.  The TOWS matrix—A tool for situational analysis , 1982 .

[5]  Marc Pfister,et al.  Model‐Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry , 2010, Journal of clinical pharmacology.

[6]  N H Holford,et al.  Concepts and usefulness of pharmacokinetic‐pharmacodynamic modelling , 1990, Fundamental & clinical pharmacology.

[7]  Charles W. Dement,et al.  Challenges in the transition to model-based development , 2008, The AAPS Journal.

[8]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[9]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[10]  Vikram Sinha,et al.  Model-Based Drug Development: The Road to Quantitative Pharmacology , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[12]  J R Koup,et al.  Impact of Population Pharmacokinetic-Pharmacodynamic Analyses on the Drug Development Process , 2000, Clinical pharmacokinetics.

[13]  Liping Zhang,et al.  The current role of model-based drug development , 2010, Expert opinion on drug discovery.

[14]  T H Grasela,et al.  Pharmacometrics and the Transition to Model‐Based Development , 2007, Clinical pharmacology and therapeutics.

[15]  C Garnett,et al.  Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.

[16]  S. Coons.  The FDA's critical path initiative: a brief introduction. , 2009, Clinical therapeutics.

[17]  Yaning Wang,et al.  Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004–2006 , 2008, Journal of clinical pharmacology.

[18]  J. L. Bower,et al.  Business policy: text and cases , 1973 .

[19]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[20]  Carl Peck,et al.  An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development , 1997, Clinical pharmacokinetics.

[21]  Yaning Wang,et al.  Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications , 2005, The AAPS Journal.

[22]  Marc Pfister,et al.  Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development , 2008, The AAPS Journal.